Form 4: Avidity Director Sells Shares in Novartis Merger

Avidity Biosciences director Arthur A. Levin disposed of all his common stock and stock options as part of the previously announced merger with Novartis AG.

Summary

• Director Arthur A. Levin disposed of all his direct and indirect holdings in Avidity Biosciences, Inc. on February 27, 2026.
• This disposal was a direct result of the Agreement and Plan of Merger, dated October 25, 2025, with Novartis AG.
• Mr. Levin disposed of 16,562 shares of common stock held directly and 131,372 shares held indirectly through a family trust.
• All stock options were also disposed of, converted into a cash payment equal to the excess of the merger consideration of $72.00 over their respective exercise prices.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development for Avidity Biosciences shareholders, as it confirms the execution of a merger agreement at a specified premium, providing a clear exit strategy and value realization.

Positives

• The disposal of shares and options is part of a merger agreement, indicating a successful acquisition for shareholders at a fixed price.
• The merger consideration of $72.00 per share provides a clear valuation for the disposed securities.

Future Outlook

The filing indicates the completion of a merger, suggesting Avidity Biosciences will no longer be a standalone publicly traded entity. The future outlook for the company's assets and operations is now integrated into Novartis AG's strategic plans.

Industry Context

StockSavvy.ai notes that this Form 4 signals the final stages of Avidity Biosciences' acquisition by Novartis AG, a common strategy in the biotechnology and pharmaceutical sectors where larger companies acquire innovative smaller firms to expand their pipelines and market share. This transaction reflects ongoing consolidation trends in the life sciences industry.

Comparison to Industry Standards

• StockSavvy.ai observes that a merger consideration of $72.00 per share for Avidity Biosciences, a clinical-stage biotechnology company, aligns with typical acquisition premiums seen in the biotech sector for companies with promising therapeutic platforms.
• Similar acquisitions, such as Gilead Sciences' acquisition of Immunomedics for $21 billion (approximately $88 per share) or Bristol Myers Squibb's acquisition of MyoKardia for $13.1 billion (approximately $225 per share), demonstrate the high valuations placed on innovative drug developers, especially those with late-stage or approved assets.
• While specific comparable projects are not detailed in this Form 4, the $72.00 price point suggests a significant premium over Avidity's pre-merger trading levels, consistent with industry benchmarks for strategic acquisitions.

Related Party Transactions

• Disposal of shares held indirectly by a family trust, which is a related party to the director, as part of the merger.

Stakeholder Impact

• Shareholders: Realization of value at $72.00 per share due to the merger.
• Employees: Potential integration into Novartis AG, with possible changes in roles or structure.
• Customers/Suppliers: Avidity's products/services will now be under Novartis's management.

Next Steps

• Completion of the merger process between Avidity Biosciences and Novartis AG.
• Integration of Avidity Biosciences' operations and assets into Novartis AG.

Key Dates

Recommendation

The filing details a director's disposal of all common stock and options in Avidity Biosciences, Inc. as a direct result of the previously announced merger agreement with Novartis AG at a consideration of $72.00 per share. For investors, this transaction confirms the progression towards the merger's completion. If the stock is currently trading at or very close to $72.00, a "hold" recommendation is appropriate as the upside is limited, and the primary event (the merger) has already been factored into the price. This Form 4 primarily serves as a confirmation of an insider's compliance with reporting requirements post-merger agreement.

Keywords

Avidity Biosciences, RNAM, Novartis AG, Merger, Acquisition, Insider Trading, Form 4, Stock Options, Common Stock, Director, Arthur A. Levin